ACELYRIN

Antibody Mimetic

Also Clin3 hidradenitis suppurativa, Cin3 psoriatic arthritis, Clin2 axial spondyloarthritis; Lonigutamab Clin1 thyroid eye disease; XLRN-517 Clin0 urticaria

ACELYRIN is investing in, developing and commercializing life-changing drug therapies. ACELYRIN’s approach is to identify and develop therapeutics through efficient and ongoing collaborations with academia, big-pharma and early-stage start-ups to get the right expertise throughout the entire process. ACELYRIN’s lead candidate is izokibep, a monoclonal antibody mimetic to inhibit interleukin-17A (IL-17A) with high potency and tissue penetrance. Currently, ACELYRIN is actively investigating the potential of izokibep in diseases with perturbed IL-17A signaling. This includes Phase 2/3 trials for inflammatory diseases of the eye (Uveitis) and skin (Psoriatic Arthritis).